Home » Products » Software » CAMCI
  • Overview
  • Features
  • Requirements
  • FAQs
  • Pricing
  • Support

CAMCI® Overview


The Computer Assessment of Mild Cognitive Impairment (CAMCI®) is a self-administered, user-friendly screening tool. CAMCI is designed to provide the level of risk that the individual's cognitive performance would fall within the range of MCI if tested on a comprehensive neuropsychological test battery and reviewed by expert neuropsychologists. CAMCI tests were developed by modifying standard paper-pencil tasks, recognized for their sensitivity to Mild Cognitive Impairment. In addition, CAMCI provides tasks not often or easily assessed through paper-pencil tasks in an innovative virtual reality environment having ecological validity for older patients. In a study of 524 community-dwelling, non-demented participants, CAMCI was highly sensitive (86%) and specific (94%) in the identification of Mild Cognitive Impairment*.

 

At their own pace (average time is 25 minutes), patients participate in a series of computerized cognitive tasks, tapping multiple cognitive domains. The patient’s report is immediately generated for on-screen inspection or to be printed for the interpreting physician. This report contains the patient’s overall performance and an interpretation of results, as well as a thorough account of domain and task level performance.

 

CAMCI is intended for use as a regular screening tool to track subtle, non age-related cognitive decline**. The patient self-administers CAMCI, requiring no direct supervision by the physician or office staff. CAMCI is user-friendly, and requires no training, specific education, or previous computer use. The interpretation of the report must be performed by a qualified health care professional. Current reporting features use normative data collected from elderly subjects age 60+.

 

Cognitive Domains Tested:

Attention

Executive Function

Memory (Verbal, Nonverbal, Functional and Incidental)

Processing Speed

 

CAMCI is billable under CPT code 96120 (Neuropsychological testing administered by a computer). The reimbursement covers the neuropsychological testing by a computer and the interpretation and reporting time for the physician or clinical psychologist.

 

Effective 01-01-06: Medicare Part B coverage of neuropsychological tests is authorized under section 1861(s)(2)(C) of the Social Security Act. Payment for neuropsychological tests is authorized under section 1842 (b)(2)(A) of the Social Security Act.

 

*Saxton et al. Computer assessment of mild cognitive impairment. Postgraduate Medicine. 2009; 121(2):177-185.

 

**CAMCI is intended as a screening tool for detecting cognitive decline at the earliest stages in an effort to allow physician directed therapeutic intervention to occur. This intervention would potentially slow the progression of Mild Cognitive Impairment (MCI) as a precursor to Alzheimer’s Disease (AD). In a clinical setting, the results of the CAMCI (when interpreted by a qualified healthcare provider), may be used as a screening aid to assist in determining whether or not a particular individual should be referred for further neuropsychological evaluation (e.g., a complete neuropsychological exam). CAMCI does not directly offer a medical diagnosis of any type. A diagnosis of MCI, dementia, or similar disease can only be made by a qualified physician or psychologist considering a wide range of potential contributing factors. Consistent with this stated intended use, PST has no indication that this tool is or should be considered a Medical Device by the FDA.

The product may also be used for research purposes for any range of cognitive related assessments. If used for research purposes, all use of the product must be in compliance with appropriate human subjects' procedures as they exist within the researchers’ institution and will be the researcher’s obligation. All such human subject protections will under no circumstances be less than those required to be afforded to research subjects under the provisions of Section 45 CFR 46 of the Code of Federal Regulations.

CAMCI® Features


  • Highly sensitive (89%) and specific (94%) screening tool
  • Self-administered
  • User-friendly
  • Several cognitive domains tested
    • Attention
    • Executive Function
    • Processing Speed
    • Memory
      • Verbal
      • Nonverbal
      • Functional
      • Incidental
  • Accuracy and response times tracked and reported
  • Report immediately available to view on-screen or to print
  • Report of performance at overall level, domain, and task level
  • Reimbursable under CPT code 96120
  • Pre-installed on a Tablet PC (Motion J3400)
    • Sealed design is easily cleaned and disinfected
    • Ergonomic
    • Portable
    • Lightweight
    • Integrated digital camera
    • Natural pen/speech input
    • Optimal viewing in all light conditions

 

CAMCI® Requirement


  • CAMCI comes pre-installed on a Tablet PC; it is currently not supported on any other platform.

CAMCI® FAQs


Q: What research has been conducted showing the ability of CAMCI to detect MCI?

A: CAMCI yielded sensitivity of 86% and specificity of 94% in a study of 524 community-dwelling, non-demented participants*. This analysis compared the CAMCI results to the adjudication of each participant (performed by trained neuropsychologists) using a full neuropsychological battery.

*Saxton et al. Computer assessment of mild cognitive impairment. Postgraduate Medicine. 2009; 121(2):177-185.

 

Q: Is CAMCI being used in any other research studies?

A: CAMCI is currently in use in research studies addressing cognitive assessment of primary care patients, intervention in dementia, traumatic brain injury, HIV-related cognitive decline, mobility assessment, and exercise interventions, as well as in studies examining the elderly and arthritis.

 

 

Q: Can elderly patients use a computer?

A: Over 1,000 elderly participants have used the CAMCI with overwhelmingly positive results. Not one participant has been unable to complete the CAMCI battery of tasks due to an inability to use a computer.

 

Q: What tests are involved?

A: CAMCI includes tests of simple attention, visual and verbal memory, executive abilities, and working memory. A virtual reality driving task provides an innovative approach to testing domains, such as prospective memory, not often assessed by paper-pencil tasks.

 

Q: When are the results available?

A: Results are available immediately! The patient’s report is immediately generated for on-screen inspection or to be printed for the interpreting physician.

 

Q: What does the report consist of?

A: The report contains the patient’s overall performance and an interpretation of results, as well as a thorough account of domain and task level performance.

 

Q: Does Medicare cover CAMCI testing?

A: CAMCI is billable under CPT code 96120 (Neuropsychological testing administered by a computer). The reimbursement covers the neuropsychological testing by a computer and the interpretation and reporting time for the physician or clinical psychologist.

Effective 01-01-06: Medicare Part B coverage of neuropsychological tests is authorized under section 1861(s)(2)(C) of the Social Security Act. Payment for neuropsychological tests is authorized under section 1842 (b)(2)(A) of the Social Security Act.

CAMCI® Pricing


CAMCI is in the commercialization process and is not yet available for purchase. 

 

Please email us at sales@pstnet.com for more information or to be added to our list for notification when CAMCI becomes available.

CAMCI® Support


For technical support please visit our Product Service and Support Website.

CAMCI®-Research Gallery


Privacy | Terms of Use | Terms and Conditions | Legal Trademarks | Authorized Use | Quality Policy
Copyright 2017 Psychology Software Tools, Inc. All Rights Reserved
Email: Info@pstnet.com | Telephone: 412.449.0078 | Fax: 412.449.0079